Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression inhuman carotid atheroma

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 331-337

  Clancy, Paula ^a   Seto, Sai Wang ^a   Koblar, Simon A ^b   Golledge, Jonathan ^a,c  

^a JAMES COOK UNIVERSITY   (Australia)

^b Division of Medicine   (Australia)

^c TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Angiotensin converting enzyme; Angiotensin II; Angiotensin receptor type 1; Atheroma; Elastin; Interstitial collagenase; Matrix metalloproteinase

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; COLLAGENASE 3; DX 600; DX600; ELASTIN; ILOMASTAT; INTERSTITIAL COLLAGENASE; IRBESARTAN; NEUTROPHIL COLLAGENASE; QUINAPRIL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROMA; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT;

ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR TYPE 1; ATHEROMA; ELASTIN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIPHENYL COMPOUNDS; CAROTID ARTERY DISEASES; COLLAGENASES; DIPEPTIDES; ELASTIN; ENDARTERECTOMY, CAROTID; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE INHIBITORS; ORGAN CULTURE TECHNIQUES; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; PLAQUE, ATHEROSCLEROTIC; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; TETRAHYDROISOQUINOLINES; TETRAZOLES;

EID: 84880402960     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.05.022     Document Type: Article

References (29)

1. Golledge J., Greenhalgh R.M., Davies A.H. The symptomatic carotid plaque. Stroke 2000, 31:774-781.
2. Sukhova G.K., Schonbeck U., Rabkin E., et al. Evidence for increased Collagenolysis by interstitial Collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999, 99:2503-2509.
3. Fulop T., Wei S.M., Robert L., Jacob M.P. Determination of elastin peptides in normal and arteriosclerotic human sera by ELISA. Clin Physiol Biochem 1990, 8(6):273-282.
4. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. JClin Invest 1994, 94:1149-1158.
5. Herman M.P., Sukhova G.K., Libby P., et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899-1904.
6. Montecucco F., Pende A., Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009, [published online April 14, 2009].
7. 2-dependent matrix metalloproteinase activity. Circulation 2004, 109:1482-1488.
8. Cipollone F., Fazia M.L., Mezetti A. Role of angiotensin II receptor blockers in atherosclerotic plaque stability. Expert Opin Pharmacother 2006, 7:277-285.
9. Legedz L., Randon J., Sessa C., et al. Cathepsin G is associated with atheroma formation in human carotid artery. JHypertens 2004, 22:157-166.
10. Ohishi M., Ueda M., Rakugi H., et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. JHypertens 1997, 15:1295-1302.
11. Sluimer J.C., Gasc J.M., Hamming I., et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. JPathol 2008, 215:273-279.
12. Golledge J., Mangan S., Clancy P. Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas. Stroke 2007, 38:1501-1508.
13. Mangan S., Clancy P., Golledge J. Modulation of endothelial cell thrombomodulin by PPAR ligands - variation according to environment. Thromb Res 2007, 121:827-834.
14. Bae S.K., Kim M.-J., Shim E.-J., et al. HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. Biomed Chromatogr 2009, 23:568-572.
15. Pool J.L., Guthrie R.M., Littlejohn T.W., et al. Dose-related antihypertensive effects of Irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998, 11:462-470.
16. Halstenson C.E., Opsahl J.A., Rachael K., et al. The pharmacokinetics of Quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function. JClin Pharmacol 1992, 32:344-350.
17. Huang L., Sexton D.J., Skogerson K., et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. JBiol Chem 2003, 278(18):15532-15540.
18. Petersen E., Wagberg F., Angquist K.-A. Serum concentrations of elastin-derived peptides in patients with specific manifestations of atherosclerostic disease. Eur J Vasc Endovasc Surg 2002, 24:440-444.
19. Christen Y., Waeber B., Nussberger J., et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin 1 and II. Circulation 1991, 83:1333-1342.
20. Mazzolai L., Pedrazzini T., Nicoud F., Gabbiani G., Brunner H.R., Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000, 35:985-991.
21. Ennezat P.V., Berlowitz M., Sonnenblick E.H., Le Jemtel T.H. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000, 2:258-262.
22. 2 receptors. Clin Sci 2011, 121:297-303.
23. Chen H., Li D., Mehta J.L. Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-ΚB by losartan in hypercholesterolemic rabbits. JCardiovasc Pharmacol 2002, 39:332-339.
24. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990, 66:883-890.
25. Ihara M., Urata H., Kinoshita A., et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399-1405.
26. Rykl J., Thiemann J., Kurzawski S., et al. Renal cathepsin G and angiotensin II generation. JHypertens 2006, 24:1797-1807.
27. Eto H., Biro S., Miyata M., et al. Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodelling after vascular injury. Cardiovasc Res 2003, 59:200-211.
28. Keeley F.W., Elmoselhi A., Leenen F.H.H. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol 1992, 262:H1013-H1021.
29. Guo J., Bot I., de Nooijer R., et al. Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. Cardiovasc Res 2009, 81:278-285.